Interleukin-2 (IL-2) Augments the Expression of Transforming Growth Factor Beta in Patients with Disseminated Cancer
- 1 January 1993
- book chapter
- Published by Springer Nature
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Alterations of Platelet Function Induced by Interleukin-2Journal of Immunotherapy, 1991
- Thrombocytopenia during immunotherapy with interleukin-2 by constant infusionThe American Journal of Medicine, 1990
- γ‐Interferon‐Induced Activation of Latent Transforming Growth Factor‐β by Human MonocytesAnnals of the New York Academy of Sciences, 1990
- Induction of circulating tumor necrosis factor (TNFα) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patientsJournal of Clinical Immunology, 1988
- Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1JNCI Journal of the National Cancer Institute, 1988
- Transforming Growth Factor βAdvances in Cancer Research, 1988
- Bone-derived and recombinant transforming growth factor β′S are potent inhibitors of tumor cell growthBiochemical and Biophysical Research Communications, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Production of multiple cytokines by clones of human large granular lymphocytesCancer Immunology, Immunotherapy, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982